HANSOH PHARMAC. HD-00001 (F:3KY) — Market Cap & Net Worth
Market Cap & Net Worth: HANSOH PHARMAC. HD-00001 (3KY)
HANSOH PHARMAC. HD-00001 (F:3KY) has a market capitalization of $22.06 Billion (€18.87 Billion) as of September 16, 2026. Listed on the F stock exchange, this Germany-based company holds position #1182 globally and #269 in its home market, demonstrating a -6.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HANSOH PHARMAC. HD-00001's stock price €3.68 by its total outstanding shares 6062955423 (6.06 Billion). Also see 3KY asset base for a full breakdown of the balance sheet.
HANSOH PHARMAC. HD-00001 Market Cap History: 2019 to 2026
HANSOH PHARMAC. HD-00001's market capitalization history from 2019 to 2026. Data shows growth from $12.03 Billion to $26.09 Billion (17.64% CAGR). Also see HANSOH PHARMAC. HD-00001 operating cash flow efficiency for how efficiently the company converts equity into cash flow.
HANSOH PHARMAC. HD-00001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HANSOH PHARMAC. HD-00001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 3KY share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.84x
HANSOH PHARMAC. HD-00001's market cap is 1.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.98x
HANSOH PHARMAC. HD-00001's market cap is 4.98 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $8.88 Billion | $9.94 Billion | $2.71 Billion | 0.89x | 3.27x |
| 2022 | $8.75 Billion | $9.38 Billion | $2.58 Billion | 0.93x | 3.38x |
| 2023 | $9.84 Billion | $10.10 Billion | $3.28 Billion | 0.97x | 3.00x |
| 2024 | $14.60 Billion | $12.26 Billion | $4.37 Billion | 1.19x | 3.34x |
| 2025 | $27.64 Billion | $15.03 Billion | $5.56 Billion | 1.84x | 4.98x |
Competitor Companies of 3KY by Market Capitalization
Companies near HANSOH PHARMAC. HD-00001 in the global market cap rankings as of September 16, 2026. Review HANSOH PHARMAC. HD-00001 tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to HANSOH PHARMAC. HD-00001 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
HANSOH PHARMAC. HD-00001 Historical Marketcap From 2019 to 2026
Between 2019 and today, HANSOH PHARMAC. HD-00001's market cap moved from $12.03 Billion to $ 26.09 Billion, with a yearly change of 17.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €26.09 Billion | -5.62% |
| 2025 | €27.64 Billion | +89.32% |
| 2024 | €14.60 Billion | +48.35% |
| 2023 | €9.84 Billion | +12.55% |
| 2022 | €8.75 Billion | -1.55% |
| 2021 | €8.88 Billion | -45.02% |
| 2020 | €16.16 Billion | +34.28% |
| 2019 | €12.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of HANSOH PHARMAC. HD-00001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.06 Billion USD |
| MoneyControl | $22.06 Billion USD |
| MarketWatch | $22.06 Billion USD |
| marketcap.company | $22.06 Billion USD |
| Reuters | $22.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HANSOH PHARMAC. HD-00001
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products … Read more